JP7264867B2 - 非メラノーマ皮膚癌(nmsc)の予防および治療 - Google Patents

非メラノーマ皮膚癌(nmsc)の予防および治療 Download PDF

Info

Publication number
JP7264867B2
JP7264867B2 JP2020503100A JP2020503100A JP7264867B2 JP 7264867 B2 JP7264867 B2 JP 7264867B2 JP 2020503100 A JP2020503100 A JP 2020503100A JP 2020503100 A JP2020503100 A JP 2020503100A JP 7264867 B2 JP7264867 B2 JP 7264867B2
Authority
JP
Japan
Prior art keywords
mrna
residues
ifn
human
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020503100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515644A (ja
JP2020515644A5 (cg-RX-API-DMAC7.html
Inventor
マルクス・マントラー
アヒム・シュネーベルガー
ヴァルター・シュミット
フランク・マットナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accanis Biotech F&e & Co KG GmbH
Original Assignee
Accanis Biotech F&e & Co KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accanis Biotech F&e & Co KG GmbH filed Critical Accanis Biotech F&e & Co KG GmbH
Publication of JP2020515644A publication Critical patent/JP2020515644A/ja
Publication of JP2020515644A5 publication Critical patent/JP2020515644A5/ja
Application granted granted Critical
Publication of JP7264867B2 publication Critical patent/JP7264867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
JP2020503100A 2017-03-31 2018-03-29 非メラノーマ皮膚癌(nmsc)の予防および治療 Active JP7264867B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17164257 2017-03-31
EP17164257.2 2017-03-31
EP17200162.0 2017-11-06
EP17200162 2017-11-06
PCT/EP2018/058036 WO2018178215A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc)

Publications (3)

Publication Number Publication Date
JP2020515644A JP2020515644A (ja) 2020-05-28
JP2020515644A5 JP2020515644A5 (cg-RX-API-DMAC7.html) 2021-04-15
JP7264867B2 true JP7264867B2 (ja) 2023-04-25

Family

ID=61763994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503100A Active JP7264867B2 (ja) 2017-03-31 2018-03-29 非メラノーマ皮膚癌(nmsc)の予防および治療

Country Status (8)

Country Link
US (1) US20200038487A1 (cg-RX-API-DMAC7.html)
EP (2) EP4019037A1 (cg-RX-API-DMAC7.html)
JP (1) JP7264867B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190133216A (cg-RX-API-DMAC7.html)
CN (1) CN110636854A (cg-RX-API-DMAC7.html)
AU (1) AU2018246292A1 (cg-RX-API-DMAC7.html)
CA (1) CA3057768A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018178215A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101987591B1 (ko) * 2018-08-06 2019-06-10 국립해양생물자원관 인게놀 메부테이트에 특이적으로 결합하는 핵산 앱타머 및 그 용도
US11685766B2 (en) 2019-05-08 2023-06-27 Creighton University 14-3-3 targeting peptides for cancer treatment
US11518784B2 (en) 2019-05-08 2022-12-06 Creighton University 14-3-3 targeting peptides for cancer treatment
NL2025475B1 (en) * 2020-04-30 2021-11-09 Ribopro B V Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity
CN115887495A (zh) * 2022-07-11 2023-04-04 上海默多赛生物科技有限公司 化学修饰的mRNA转染的皮片或皮瓣及其促进创面愈合的用途
CN116785501A (zh) * 2022-08-04 2023-09-22 上海交通大学医学院附属上海儿童医学中心 促进心脏组织修复的modRNA转染改造的细胞及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514076A (ja) 2012-03-26 2015-05-18 バイオンテック アーゲー 免疫療法のためのrna製剤
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA873743B (en) * 1986-05-27 1987-11-25 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
WO1990000406A1 (en) 1988-07-05 1990-01-25 Schering Corporation Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
IL129387A0 (en) 1996-10-18 2000-02-17 Canji Inc Methods and compositions for delivery and expression of interferon-alpha nucleic acids
CA2323604A1 (en) 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
CA2990881C (en) 2015-06-30 2024-02-20 Ethris Gmbh Utrs increasing the translation efficiency of rna molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514076A (ja) 2012-03-26 2015-05-18 バイオンテック アーゲー 免疫療法のためのrna製剤
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clin. Dermatol. (2004) vol.22, issue 3, p.183-188

Also Published As

Publication number Publication date
EP3600379A1 (en) 2020-02-05
CN110636854A (zh) 2019-12-31
JP2020515644A (ja) 2020-05-28
CA3057768A1 (en) 2018-10-04
KR20190133216A (ko) 2019-12-02
US20200038487A1 (en) 2020-02-06
AU2018246292A1 (en) 2019-10-10
EP3600379B1 (en) 2022-12-21
WO2018178215A1 (en) 2018-10-04
EP4019037A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
EP3600379B1 (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
KR101361416B1 (ko) 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
JP2003525222A (ja) Il−12をコードする核酸分子の腫瘍内投与
JP2023145532A (ja) 局所皮膚低栄養状態の治療
JP5667043B2 (ja) 阻害性オリゴヌクレオチドを送達するための組成物および方法
JP2023548831A (ja) 腫瘍溶解性ウイルスが有効なtil療法のためにt細胞応答を強化する
Okada et al. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector
JP2015091826A (ja) 癌治療用の組合せ製品
Liu et al. Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line
US20180117176A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity
HK40067000A (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
Sponza et al. Role of the interferon-inducible IFI16 gene in the induction of ICAM-1 by TNF-α
WO2016112849A1 (zh) I型干扰素及间充质干细胞在制备抗肿瘤药物中的新用途
US20240139345A1 (en) Nucleic acid vectors and methods of use
CN117280029A (zh) 核酸载体和使用方法
AU2006325752B2 (en) Use of eIF-5A to kill multiple myeloma cells
JPWO2005010185A1 (ja) Klf5遺伝子の発現を抑制するrna
US20190298763A1 (en) Use of dna netosis to deliver trail for cancer therapy
AU2008288846A1 (en) Methods and compositions for post-transcriptional gene silencing
EP2708236A1 (en) Tumor treatment
WO2021193081A1 (ja) 1型単純ヘルペスウイルス
CN103127492A (zh) 一种抗丙型肝炎病毒的蛋白及其用途
US20250109409A1 (en) RIG1 Inhibition and Therapeutic Viral Protein Expression
Zhang et al. IFN-γ Enhances the Efficacy of Exosomes Derived from Mesenchymal Stem Cells in Myocardial Infarction Rats via miR-21 Stimulated by STAT1
Double-Stem-Loop 644. Decreased Generation and Cytotoxic Function of Adenovirus-Specific CD8 T Cells in Both CD28 and FasL Deficient Mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230413

R150 Certificate of patent or registration of utility model

Ref document number: 7264867

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150